Artelo Biosciences
Develops cannabinoid and fatty-acid-binding-protein drug candidates for cancer supportive care and pain.
Something off on this page? Send us feedback.
Profile
Develops prescription drug candidates that modulate cannabinoid receptors and fatty-acid-binding proteins, with ART27.13, ART26.12 and ART12.11 spanning cancer supportive care, pain and neuropsychiatric research. It has no marketed products and relies on outsourced development and licensed intellectual property.
Develops small-molecule medicines that modulate lipid signaling, particularly cannabinoid receptors and fatty-acid-binding proteins, for regulated prescription treatment of unmet needs. Its portfolio includes ART27.13 for cancer-related anorexia/cachexia and glaucoma or ocular hypertension, ART26.12 for chemotherapy-induced peripheral neuropathy and related research, and ART12.11, an oral cannabidiol-tetramethylpyrazine cocrystal under preclinical study.
Operates from the United States with subsidiaries, collaborators and clinical activity across the United Kingdom, Ireland, Canada and other countries. Development is conducted through employees, consultants, clinical investigators and contract research and manufacturing organizations; the company owns no laboratories or manufacturing facilities. ART27.13 and the FABP platform depend on exclusive licenses that carry diligence, milestone and royalty obligations.
Company facts
Key statistics
Year to date −47.8% · Average volume (30d) 475.5K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.72 | −$0.89 | −23.6% | — | — | — | −1.57% |
| May 14, 2026Q1 FY26 | −$0.78 | −$4.00 | −412.8% | — | — | — | −21.37% |
| Feb 24, 2026Q4 FY25 | −$4.71 | −$6.66 | −41.4% | — | — | — | −6.92% |
| Nov 12, 2025Q3 FY25 | −$0.82 | −$3.97 | −384.1% | — | — | — | 0.00% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$2.4M | −$3.2M | −$3.1M | −$2.8M | −$2.7M | −$2.5M | |
| Net income | −$2.4M | −$3.2M | −$3.1M | −$4.2M | −$3.0M | −$2.4M | |
| Diluted EPS | −$0.24 | −$1.87 | −$1.32 | −$2.04 | −$4.00 | −$0.89 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $4.2M · Total debt $49.0K · Total assets $6.5M · Shareholders' equity $5.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 3.49M · Float 2.17M · 62.4% free float
Insiders — no current Form 4 position.
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 235.8K | 9.99% | 13G | May 15, 2026 |
| Mitchell P. Kopin | 81.7K | 9.99% | 13G | Apr 3, 2026 |
| Kathmere Capital Management, LLC | 13.3K | 0.38% | 13F | Apr 28, 2026 |
| Jane Street Group, LLC | 13.1K | 0.38% | 13F | May 12, 2026 |
| Vanguard Capital Management LLC | 10.1K | 0.29% | 13F | May 15, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Pfizer
Advanced cancer-cachexia program targeting weight loss and anorexia.
- Jazz Pharmaceuticals
Prescription cannabidiol benchmark for the oral-CBD formulation field.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Artelo Biosciences | $0.7125 | +7.53% | $2.3M | — | — | — | — |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Jazz Pharmaceuticals | $244.54 | +0.02% | $15.36B | 16.7 | 9.7 | 3.3 | +15.6% |
| Median | 26.8 | 9.8 | 2.9 | +9.1% |